Controversies in HCV Therapy

Module number
Date presented
March 22, 2016 
HCV providers and multi-disciplinary team staff members 
CE Credit

On Tuesday March 22, Dr. Ira Jacobson, Chair of Medicine at Mount Sinai Beth Israel presented: “Controversies in HCV Therapy.”

About Dr. Jacobson

  • Chair of Medicine, Mount Sinai Beth Israel
  • Vice Chair of Medicine & Co-Director of the Liver Institute, Icahn School of Medicine at Mount Sinai

Dr. Jacobson earned his BS summa cum laude from Yale University and his MD from Columbia University College of Physicians and Surgeons. After completing an internship and residency at the University of California San Francisco he trained as a fellow in gastroenterology and Hepatology at Massachusetts General Hospital and Harvard Medical School. In 1984 he joined the faculty at Weill Cornell Medical College and New York Presbyterian Hospital. During his 30 years at Weill Cornell, Dr. Jacobson served as Chief of the Division of the Gastroenterology and Hepatology from 1998-2015 and was Vincent Astor Distinguished Professor of Medicine as well as Medical Director of the Center for the Study of Hepatitis C. In March 2015 he assumed the position of Chair of Medicine at Mount Sinai Beth Israel Medical Center, and Vice Chair of Medicine and co-Director of the Liver Institute at the Icahn School of Medicine at Mount Sinai.

Dr. Jacobson is a Fellow of the American College of Physicians, American College of Gastroenterology, and American Gastroenterological Association, and a member of the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. In addition to maintaining an active practice with a focus on patients with liver disease, he has been an investigator in many trials on antiviral therapy for hepatitis B and C, including the pivotal trials on interferon-based therapy, since the 1980s. He has been lead principal investigator and author of a number of trials, including the WIN-R trial (weight based ribavirin with peginterferon), ADVANCE (telaprevir), QUEST-1 (simeprevir), POSITRON (sofosbuvir), and STARTVerso3 (faldaprevir). He has served on the Gastroenterology and Transplant Hepatology Boards of the American Board of Internal Medicine, as Associate Editor of the Journal of Hepatology, and as a reviewer for several other journals. He has authored or co-authored over 250 peer-reviewed papers, chapters and reviews, including papers in the New England Journal of Medicine, Lancet, Gastroenterology, Hepatology, Journal of Hepatology, Journal of Viral Hepatitis, Clinical Gastroenterology and Hepatology, and others. He has edited two books on ERCP and a volume on hepatitis B for Clinics in Liver Disease. He has co-chaired the annual Viral Hepatitis Congress in Frankfurt, Germany since 2012. Dr. Jacobson was recently named Co-Chief Medical Editor of HCV Next, a new publication from Slack Incorporated that also appears on